Skip to main content
Premium Trial:

Request an Annual Quote

Genable Receives FDA Orphan Drug Status for Ocular Disease Drug

Premium

Genable Technologies, an Irish biopharmaceutical firm, announced last week that it has received orphan drug status from the US Food and Drug Administration for its expressed RNAi-based treatment for retinitis pigmentosa.

The disease is rare degenerative eye condition that can lead to blindness. Last summer, the company took a license to Benitec Biopharma’s expressed RNAi technology for use in developing a treatment for the condition (GSN 7/19/2012).

Genable’s drug, dubbed GT038, comprises an AAV vector to deliver an shRNA that silences both the mutant and wild-type rhodopsin gene, which is mutated in retinitis pigmentosa. The company, which previously received orphan drug status for the agent from European regulators, anticipates a phase I trial of GT038 could begin in 2014.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.